Quantitative analysis of computed tomography of the lungs in patients with lymphangioleiomyomatosis treated with sirolimus

Abstract

We aimed to study sirolimus-related lung parenchymal changes by quantitative analysis of computed tomography (CT) of the lungs in patients with lymphangioleiomyomatosis (LAM). Methods: We studied 20 participants from the Multicenter Lymphangioleiomyomatosis Sirolimus Trial for Safety study, who had undergone both thin-section CT scans and pulmonary function tests at baseline, 12, and 24 months. Quantitative CT parameters such as CT-derived total lung capacity, percentage of low attenuation area (LAA%), lung density histogram, fractal property of low attenuation area, and airway dimensions were analyzed, and correlations were conducted between the longitudinal change in each quantitative CT measurement and changes in pulmonary function were examined. Among 20 participants, pre-trial (n ¼ 8) and post-trial (n ¼ 16) CT data were also analyzed to deduce pathophysiologic implications of the serial changes in CT parameters during trial periods. Results: FEV 1 significantly increased from baseline to 24 months (slope 3.71 AE 1.50 ml/month) whereas FVC didn't during sirolimus therapy. Strikingly, LAA%, and skewness and kurtosis of density histogram significantly increased from baseline to 24 months, while mean and mode CT values significantly decreased from baseline to 24 months. Statistically significant positive correlations were found between ΔFEV 1 and Δskewness (r ¼ 0.465, p ¼ 0.045). Taking the changes in lung density during pre-trial period into consideration, sirolimus decreases the area of -800 to -750 Housefield unit (HU) density and inhibits the decrease of -950 to -800 HU area during treatment, then producing the increased LAA% during the trial and post-trial periods. Given few sirolimus-related changes in airway dimensions, possible changes in lung mechanics may have contributed to increased FEV 1 . Conclusion: Our study suggests that the lung density histogram parameters, kurtosis, and skewness, may be useful as indicators of the efficacy of sirolimus.

Perioperative management of thoracic surgery in patients with lymphangioleiomyomatosis

“…Controlling LAM is also important to treat hypoxemia. It has been reported that administration of sirolimus improved lung permeability on computed tomography (CT) [ 10 , 22 ]. The radiolucency on the X-ray in this study is the same phenomenon as permeability on CT, and may be considered as indicator of lymphatic flow stasis.…”

A Novel Computational Model for Detecting the Severity of Inflammation in Confirmed COVID-19 Patients Using Chest X-ray Images

“…This effect appears in X-ray images as bright pixels in the lungs’ shadow area. Bright pixels indicate the presence of swelling in the alveoli affected by the virus [ 35 ]: the more bright pixels, the more severe the disease. The number of dark pixels in the original image is measured in relation to the total number of pixels in both the original X-ray and the multi-colored X-ray.…”